Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec;142(6):637-640.
doi: 10.1111/ane.13322. Epub 2020 Aug 5.

Quality of life in chronic inflammatory demyelinating polyneuropathy patients treated with subcutaneous immunoglobulin

Anne-Kathrine Ryltoft  1 , Ali Al-Zuhairy  2 , Søren H Sindrup  3 , Henning Andersen  1 , Lars K Markvardsen  1   4
Affiliations

Quality of life in chronic inflammatory demyelinating polyneuropathy patients treated with subcutaneous immunoglobulin

Anne-Kathrine Ryltoft et al. Acta Neurol Scand. 2020 Dec.

Abstract

Background: Subcutaneous immunoglobulin (SCIG) is effective treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). Quality of life (QoL) increases following switch from intravenous administration to SCIG, but its correlation with clinical functioning is sparsely studied.

Aims of the study: The aim of this study is to evaluate the correlation between QoL and clinical functioning in CIDP patients treated with SCIG.

Methods: Danish patients with CIDP with a disease duration <10 years and currently treated with SCIG were eligible for inclusion. QoL was assessed with EQ-5D-5L and disability by the Overall Disability Sum Score (ODSS) and Rasch-built Overall Disability Scale (RODS). Gait performance was evaluated by a 40-meter-walk test (40-MWT) and a 6-spot-step test (6-SST) along with assessment of muscle strength (Medical Research Council score [MRC]). Correlations between QoL and the measured scores were calculated.

Results: Of 92 eligible patients, 44 were included. QoL on the visual analogue scale (VAS) was 65% (range: 15-90) of the level of healthy controls (P = .03) and correlated to impaired gait function by 40-MWT and 6-SST. QoL correlated to RODS and ODSS, whereas there was no correlation with the MRC score.

Conclusions: In SCIG treated CIDP patients QoL is reduced and correlates to gait performance and disability.

Keywords: chronic inflammatory demyelinating polyneuropathy; quality of life; subcutaneous immunoglobulin.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

REFERENCES

    1. Markvardsen LH, Debost JC, Harbo T, et al. Subcutaneous immunoglobulin in responders to intravenous therapy with chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol. 2013;20(5):836‐842.
    1. van Schaik IN, Bril V, van Geloven N, et al. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurol. 2018;17(1):35‐46.
    1. van Schaik IN, Mielke O, Bril V, et al. Long‐term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP: PATH extension study. Neurol Neuroimmunol Neuroinflamm. 2019;6(5):e590.
    1. Cocito D, Merola A, Romagnolo A, et al. Subcutaneous immunoglobulin in CIDP and MMN: a different long‐term clinical response? J Neurol Neurosurg Psychiatry. 2016;87(7):791‐793.
    1. Hartung HP, Mallick R, Bril V, et al. Patient‐reported outcomes with subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy: the PATH study. Eur J Neurol. 2020;27(1):196‐203.

MeSH terms

Substances

LinkOut - more resources